MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Show more
Cash Flow Overview
Change in Cash
-$185M
Free Cash flow
-$563M
Unit: Million (M) dollars
Positive Cash Flow Breakdown
Proceeds from maturities of mark...
Proceeds from sales of marketabl...
Deferred revenue
Others
Negative Cash Flow Breakdown
Net loss
Purchases of marketable securiti...
Inventory
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-782
-1,343
-826
-200
Stock-based compensation
120
104
113
125
Depreciation and amortization
63
59
67
52
Amortization/accretion of investments
10
11
13
17
Loss on equity investments, net
0
-2
-3
3
Other non-cash items
-4
-6
-27
-14
Accounts receivable, net
-53
-114
-859
1,013
Prepaid expenses and other assets
-16
-54
-237
-66
Inventory
132
-6
-179
91
Right-of-use assets, operating leases
-10
-11
-10
-9
Accounts payable
-8
-120
22
89
Accrued liabilities
11
464
194
199
Deferred revenue
190
5
-67
40
Operating lease liabilities
-8
-7
-6
-5
Other liabilities
-53
26
131
-112
Net cash used in operating activities
-526
-630
930
-847
Purchases of marketable securities
556
1,348
1,547
1,162
Proceeds from maturities of marketable securities
710
732
929
1,210
Proceeds from sales of marketable securities
212
602
609
685
Purchases of property, plant and equipment
37
62
39
33
Acquisition of business, net of cash acquired
-
-
0
-
Purchase of intangible asset
0
0
0
0
Investment in convertible notes and equity securities
-
-
0
-
Net cash provided by investing activities
329
-76
-48
700
Proceeds from credit facility
-
-
600
-
Payment of credit facility issuance costs
-
-
22
-
Proceeds from issuance of common stock through equity plans
23
19
16
2
Tax payments related to net share settlements on equity awards
2
2
1
0
Changes in financing lease liabilities
7
0
12
3
Net cash provided by financing activities
14
17
581
-1
Effect of changes in exchange rates on cash and cash equivalents
-2
1
0
1
Net decrease in cash, cash equivalents and restricted cash
-185
-688
1,463
-147
Cash, cash equivalents and restricted cash, beginning of year
1,909
2,597
1,626
1,626
Cash, cash equivalents and restricted cash, end of period
1,724
1,909
2,597
1,134
Page 1
Unit: Million (M) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from maturities
of marketable...
$710M
(-52.38%↓ Y/Y)
Proceeds from issuance of
common stock through...
$23M
(64.29%↑ Y/Y)
Proceeds from sales of
marketable securities
$212M
(-42.86%↓ Y/Y)
Net cash provided by
investing activities
$329M
(-41.67%↓ Y/Y)
Net cash provided by
financing activities
$14M
(55.56%↑ Y/Y)
Canceled cashflow
$593M
Canceled cashflow
$9M
Net decrease in
cash, cash...
-$185M
(46.38%↑ Y/Y)
Canceled cashflow
$343M
Deferred revenue
$190M
(95.88%↑ Y/Y)
Stock-based compensation
$120M
(-7.69%↓ Y/Y)
Depreciation and
amortization
$63M
(10.53%↑ Y/Y)
Accounts receivable, net
-$53M
(-76.67%↓ Y/Y)
Prepaid expenses and
other assets
-$16M
(-108.16%↓ Y/Y)
Accrued liabilities
$11M
(178.57%↑ Y/Y)
Right-of-use assets,
operating leases
-$10M
(0.00%↑ Y/Y)
Other non-cash items
-$4M
(88.24%↑ Y/Y)
Purchases of marketable
securities
$556M
(-57.07%↓ Y/Y)
Purchases of property,
plant and equipment
$37M
(1133.33%↑ Y/Y)
Changes in financing
lease liabilities
$7M
(40.00%↑ Y/Y)
Tax payments
related to net share...
$2M
Net cash used in
operating activities
-$526M
(42.76%↑ Y/Y)
Canceled cashflow
$467M
Effect of changes in
exchange rates on cash and...
-$2M
Net loss
-$782M
(5.21%↑ Y/Y)
Inventory
$132M
(15.79%↑ Y/Y)
Other liabilities
-$53M
(8.62%↑ Y/Y)
Amortization/accretion of investments
$10M
(-44.44%↓ Y/Y)
Operating lease
liabilities
-$8M
(-60.00%↓ Y/Y)
Accounts payable
-$8M
(82.98%↑ Y/Y)
Buy us a coffee
Master Final R&D Day 2021 Slides (09
Moderna, Inc. (MRNA)
Master Final R&D Day 2021 Slides (09
Moderna, Inc. (MRNA)